Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin

British Journal of Clinical Pharmacology

Volumn 45, Issue 2, 1998, Pages 173-175

  Simon, Nicolas ^a   Dailly, Eric ^a   Combes, Olivier ^a   Malaurie, Emmanuelle ^b   Lemaire, Michel ^c   Tillement, Jean Paul ^a   Urien, Saïk ^a,d,e  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b Hopital Intercommunal de Creteil   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d INSERM   (France)

^e FACULTÉ DE MÉDECINE   (France)

Author keywords

Binding; Blood; Lipoprotein; MDR reversion; Plasma binding; SDZ PSC 833

Indexed keywords

CYCLOSPORIN D; VALSPODAR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ERYTHROCYTE LEVEL; DRUG PROTEIN BINDING; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; PLASMA; PRIORITY JOURNAL;

CYCLOSPORINE; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; ERYTHROCYTES; HUMANS; LIPOPROTEINS; PLASMA; PROTEIN BINDING;

EID: 0031984212     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00663.x     Document Type: Article

References (10)

1. Ford JM, Hait WN. Pharmacology of drugs that alter multidnig resistance in cancer. Pharmacol Res 1990; 42: 155-199.
2. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991; 2: 225-234.
3. Urien S, Zini R, Lemaire M, Tillement JP. Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat. J Pharmacol Exp Ther 1990; 253: 305-309.
4. Urien S, Claudepierre P, Meyer J, Brandt R, Tillement JP. Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem Pharmacol 1992; 44: 1891-1893.
5. Cenni B, Meyer J, Brandt R, Betschart B. The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum. Br J Clin Pharmacol 1995; 39: 519-526.
6. Pike E, Skuterud B, Kierulf P, Lunde PKM. Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline and quinidine. Clin Pharmacol Ther 1982; 32: 599-606.
7. Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986; 22: 499-506.
8. Rowland M. Plasma protein binding and therapeutic drug monitoring. Ther Drug Monitoring 1980; 2: 29-37.
9. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994; 69: 833-839.
10. Masquelier M, Vitols S, Peterson S. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 1986; 46: 3842-3847.